Lower extremity peripheral artery disease (PAD) affects> 230 million adults worldwide and is
associated with increased risk of various adverse clinical outcomes (other cardiovascular …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Objective The aim of our study was to determine the incidence, characteristics, and clinical
outcomes of patients with the novel coronavirus (COVID-19) infection who had presented …

BIOTRONIK's First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter
vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularisation of …

Patients with widespread atherosclerosis such as peripheral artery disease (PAD) have a
high risk of cardiovascular and limb symptoms and complications, which affects their quality …

Peripheral artery disease (PAD) is a leading cause of cardiovascular morbidity and mortality;
however, the extent to which genetic factors increase risk for PAD is largely unknown. Using …

Level of evidence Level A Data obtained from multiple concordant large randomized trials
and/or robust meta-analysis of randomized clinical trials Level B Data obtained from less …

Peripheral arterial disease (PAD) represents a spectrum from asymptomatic stenosis to limb-
threatening ischemia. The last decade has seen a tremendous increase in the variety of …

Background Although supervised exercise therapy (SET) provides significant symptomatic
benefit for patients with intermittent claudication (IC), it remains an underutilized tool …

Key Clinical Points Peripheral Artery Disease Atherosclerotic peripheral artery disease
affects more than 200 million persons worldwide, including at least 8.5 million persons in the …